Literature DB >> 23786647

Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study.

Anjali Shah1, Therese M-L Andersson, Bernard Rachet, Magnus Björkholm, Paul C Lambert.   

Abstract

The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10% during the 1970s and 1980s in England. This population-based study estimated the 5-year relative survival and 'cure' for 48 380 adult patients diagnosed with AML in England during 1971-2006. Relative survival and cure mixture models were used to produce estimates of 5-year relative survival and the percentage 'cured'. 'Cure' was defined as the proportion of a group of survivors for whom there is no excess mortality compared with the general population. The 5-year relative survival and the percentage 'cured' increased for patients aged under 70 years at diagnosis during 1971-2006, but advancing age was associated with poorer outcome. During the study period a dramatic increase in 5-year relative survival occurred in those aged 15-24 years, from 7% to 53%. The percentage 'cured' was less than 10% for all ages in 1975, but increased to 45% for those aged 15-24 years in 2000. Cure could not be estimated for patients over 70 years, because survival was consistently low (<5%). The long-term outcome of patients with AML has improved substantially, particularly in younger patients. The potential exists for further increasing levels of 'cure'.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  England; acute myeloid leukaemia; cure; outcome; survival

Mesh:

Year:  2013        PMID: 23786647     DOI: 10.1111/bjh.12425

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  66 in total

1.  Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.

Authors:  Su-Min Jeong; Taewoong Choi; Dahye Kim; Kyungdo Han; Seok Jin Kim; Sang Youl Rhee; Edward L Giovannucci; Dong Wook Shin
Journal:  Leukemia       Date:  2020-12-02       Impact factor: 11.528

Review 2.  Elderly acute myeloid leukemia: assessing risk.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.

Authors:  S J Coles; M N Gilmour; R Reid; S Knapper; A K Burnett; S Man; A Tonks; R L Darley
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

4.  Early mortality and survival in older adults with acute myeloid leukemia.

Authors:  Manisha Pant; Vijaya Raj Bhatt
Journal:  Int J Hematol Oncol       Date:  2017-11-20

5.  Flow cytometry and thromboelastography to assess platelet counts and coagulation in patients with haematological malignancies.

Authors:  Alex Gatt; Fabian Bonello; Raphael Buttigieg; Samuel Debono; Patricia Brincat; Charlie Grima; Peter Gatt; Thomas Lofaro; Stefan Laspina
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

6.  Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.

Authors:  Qingxiao Hong; Xiaoying Chen; Huadan Ye; Xiaodong Wu; Xuejing Wang; Lingyan Kong; Yongming Xia; Shiwei Duan
Journal:  Oncol Lett       Date:  2017-03-10       Impact factor: 2.967

7.  Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.

Authors:  Marijn A Gillissen; Greta de Jong; Martijn Kedde; Etsuko Yasuda; Sophie E Levie; Gemma Moiset; Paul J Hensbergen; Arjen Q Bakker; Koen Wagner; Jullien Villaudy; Pauline M van Helden; Hergen Spits; Mette D Hazenberg
Journal:  Blood Adv       Date:  2017-08-18

Review 8.  Acute myelogenous leukemia in adolescents and young adults.

Authors:  Ursula Creutzig; Matthew A Kutny; Ronald Barr; Richard F Schlenk; Raul C Ribeiro
Journal:  Pediatr Blood Cancer       Date:  2018-04-18       Impact factor: 3.167

9.  ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model.

Authors:  Sargur Madabushi Srideshikan; Jamison Brooks; Darren Zuro; Bijender Kumar; James Sanchez; Liliana Echavarria Parra; Marvin Orellana; Paresh Vishwasrao; Indu Nair; Junie Chea; Kofi Poku; Nicole Bowles; Aaron Miller; Todd Ebner; Justin Molnar; Joseph Rosenthal; Daniel A Vallera; Jeffrey Y C Wong; Anthony S Stein; David Colcher; John E Shively; Paul J Yazaki; Susanta K Hui
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

10.  The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal:  Oncologist       Date:  2016-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.